Numab Therapeutics, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, successfully closes CHF 100 million (approximately USD 110 million) in Series C financing Round. The financing was co-led by new investors
Tags :Julia Schieber
Baker McKenzie has advised argenx on its strategic collaboration and exclusive license agreement with Zai Lab for the development and commercialization of efgartigimod in Greater China, including mainland China, Hong Kong, Taiwan and Macau.
Baker McKenzie advised UBS in all legal, regulatory and competition law aspects of the transaction. The team was led by Ansgar Schott (Financial Services - pictured left), Pascal Richard (pictured second left) and Petra Hanselmann (
CSL enters partnership with Thermo Fisher Scientific, a global biotechnology company with a dynamic portfolio of life-saving medicines.
The Swiss Similasan Group, which develops and produces homeopathic products and natural cosmetics since 1980, decided to establish a strategic alliance with France-based Laboratoires Thea in the area of eye care products
Deutsche Börse Group’s post-trade services provider Clearstream and Ubs have agreed on a partnership in the investment fund services business segment.
